, Volume 253, Issue 4 Supplement, pp iv16-iv21

Clinical studies with ropinirole in Parkinson’s disease and RLS

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Ropinirole is a modern dopamine agonist with a halflife of medium extent that is highly selective for D2-receptors. Ropinirole is an indole derivative and thus does not belong to the group of ergoline dopamine receptor agonists. Its effect has been proved in a number of controlled studies in both monotherapy and combination treatments of Parkinson’s disease. We can meanwhile refer to the long-term data of studies that have been run for more than 10 years. The substance has also been approved for the management of restless legs syndrome. A long-acting formula of the substance will be available soon.